You have probably never heard of 2,5-dimethoxy-4-iodoamphetamine (DOI), much less worried about its possible abuse. Yet the Drug Enforcement Administration (DEA) wants to ban this synthetic psychedelic, a promising research chemical used in more than 900 published studies, by placing it in Schedule I of the Controlled Substances Act. Students for Sensible Drug Policy (SSDP), which defeated a previous DEA attempt to ban DOI in 2022, is determined to stop the agency's interference with science again.
A DEA administrative law judge has scheduled a 10-day hearing on the proposed ban, beginning on November 12. SSDP, which filed a prehearing statement on behalf of more than 20 scientists, argues that placing DOI in Schedule I would impose "onerous financial and bureaucratic obstacles on researchers." SSDP also opposes the scheduling of another psychedelic, 2,5-dimethoxy-4-chloroamphetamine (DOC), under the same proposed rule, which the DEA published last December.
